Funder: National Institutes of Health

Due Dates: June 16, 2025 (New) | July 16, 2025 (Renewal/Resubmission/Revision) | October 16, 2025 (New) | November 16, 2025 (Renewal/Resubmission/Revision) | February 16, 2026 (New) | March 16, 2026 (Renewal/Resubmission/Revision) | June 16, 2026 (New) | July 16, 2026 (Renewal/Resubmission/Revision)

Funding Amounts: Up to $275,000 direct costs over 2 years; no more than $200,000 in any single year; maximum project period is 2 years.

Summary: Supports exploratory research to elucidate mechanisms underlying neuropsychiatric symptoms in Alzheimer's disease and related dementias, aiming to identify novel therapeutic targets.

Key Information: R21 mechanism; clinical trial optional; updated March 31, 2025—review full FOA for recent changes.